MX2021015465A - Vacuna para fiebre porcina africana. - Google Patents

Vacuna para fiebre porcina africana.

Info

Publication number
MX2021015465A
MX2021015465A MX2021015465A MX2021015465A MX2021015465A MX 2021015465 A MX2021015465 A MX 2021015465A MX 2021015465 A MX2021015465 A MX 2021015465A MX 2021015465 A MX2021015465 A MX 2021015465A MX 2021015465 A MX2021015465 A MX 2021015465A
Authority
MX
Mexico
Prior art keywords
compositions
peptides
animal
administration
swine fever
Prior art date
Application number
MX2021015465A
Other languages
English (en)
Inventor
Avner Finger
Avi Zrachya
Ofer Cohen
Anat Zvi
Original Assignee
Phibro Animal Health Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phibro Animal Health Corporation filed Critical Phibro Animal Health Corporation
Publication of MX2021015465A publication Critical patent/MX2021015465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Se describen en la presente péptidos predichos para ser inmunogénicos contra el virus de fiebre porcina Africana (ASFV) y composiciones de vacuna que incluyen los péptidos. En algunas modalidades, estas composiciones comprenden o consisten de uno o más péptidos que comprenden las secuencias de aminoácidos expuestas en SEQ ID NOs: 2-2273. En otras modalidades, las composiciones comprenden vectores virales o células hospederas, o combinaciones de los mismos, que comprenden uno o más de los péptidos. En otras modalidades, las composiciones comprenden moléculas de ácido nucleico que comprenden uno o más de los péptidos. Las composiciones descritas pueden incluir uno o más componentes adicionales, tales como, pero no limitados a, un portador, un adyuvante, un agente terapéutico adicional, o combinaciones de los mismos. Se describen recipientes y kits que comprenden las composiciones. Los usos de las composiciones pueden incluir la administración a un animal para inducir una respuesta inmune en el animal, o para inmunizar al animal contra ASFV. La administración se puede realizar utilizando uno o más de varios métodos como es descrito en la presente, tal como la administración intramuscular o intranasal.
MX2021015465A 2019-06-28 2020-06-26 Vacuna para fiebre porcina africana. MX2021015465A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868483P 2019-06-28 2019-06-28
US201962941381P 2019-11-27 2019-11-27
PCT/US2020/039846 WO2020264312A1 (en) 2019-06-28 2020-06-26 African swine fever vaccine

Publications (1)

Publication Number Publication Date
MX2021015465A true MX2021015465A (es) 2022-03-11

Family

ID=71728905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015465A MX2021015465A (es) 2019-06-28 2020-06-26 Vacuna para fiebre porcina africana.

Country Status (10)

Country Link
US (1) US20220105170A1 (es)
EP (1) EP3990012A1 (es)
JP (1) JP2022538673A (es)
KR (1) KR20220031028A (es)
CN (1) CN113454102A (es)
AU (1) AU2020304652A1 (es)
BR (1) BR112021026439A2 (es)
CA (1) CA3145228A1 (es)
MX (1) MX2021015465A (es)
WO (1) WO2020264312A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111944017B (zh) * 2020-08-26 2022-03-04 中国农业科学院兰州兽医研究所 一类促进猪机体产生广谱获得性免疫应答的多肽及其应用
CN111925416B (zh) * 2020-08-26 2021-12-17 中国农业科学院兰州兽医研究所 一类促进猪机体产生广谱获得性免疫应答的多肽及其应用
CN114044806B (zh) * 2020-08-26 2023-10-24 中国农业科学院兰州兽医研究所 一类促进猪机体产生广谱性免疫应答的多肽及其应用
CN112724203A (zh) * 2020-12-30 2021-04-30 郑州大学 一种非洲猪瘟病毒p54蛋白抗原表位肽及其应用
CN113061588B (zh) * 2021-05-20 2023-08-01 军事科学院军事医学研究院军事兽医研究所 缺失i226r基因的非洲猪瘟病毒减毒株及其活疫苗
CN113755505B (zh) * 2021-09-30 2023-05-02 绵阳市游仙区创新科技产业技术研究院 治疗和/或预防非洲猪瘟病毒的疫苗及其制备方法
WO2024031045A2 (en) * 2022-08-04 2024-02-08 Malcolm Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
US11969453B2 (en) 2023-06-14 2024-04-30 Nae Woi Korea., Ltd. Horseradish and cinnamon mixed extract composition for suppression of avian viral epidemic diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422805A1 (en) 2003-12-24 2012-02-29 Ramot at Tel-Aviv University Ltd. Antiviral preparations obtained from a natural cinnamon extract
US8008268B2 (en) * 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2401276B1 (es) * 2011-10-04 2014-02-19 Fundació Centre De Recerca En Sanitat Animal Utilización de una construcción genica y/o peptídica para la fabricación de una vacuna para la prevención y/o tratamiento de la infección causada por el virus de la peste porcina africana (vppa).
CN103805615A (zh) * 2014-02-19 2014-05-21 孙洁 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using

Also Published As

Publication number Publication date
AU2020304652A1 (en) 2022-02-24
BR112021026439A2 (pt) 2022-02-15
KR20220031028A (ko) 2022-03-11
EP3990012A1 (en) 2022-05-04
CN113454102A (zh) 2021-09-28
WO2020264312A1 (en) 2020-12-30
JP2022538673A (ja) 2022-09-05
US20220105170A1 (en) 2022-04-07
CA3145228A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2021015465A (es) Vacuna para fiebre porcina africana.
PH12021550580A1 (en) African swine fever virus vaccine
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
RU2020132040A (ru) Общие неоантигены
RU2015135890A (ru) Композиция вакцины
NZ601345A (en) Combination adjuvant formulation
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2014534202A5 (es)
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
AR110632A1 (es) Vectores del adenovirus canino
CL2020000295A1 (es) Métodos de terapia génica del factor viii (fviii)
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
AU2017313064B2 (en) Methods and compositions for targeted gene transfer
RU2018116601A (ru) Иммунногенный слитый белок
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
NZ598605A (en) Vaccine against african horse sickness virus
RU2018122755A (ru) Слитые белки fmdv-e2 и их применение
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
MX2017014417A (es) Vacunas contra el dengue.